Pembrolizumab in Association With the IMA950/Poly-ICLC for Relapsing Glioblastoma
Status:
Recruiting
Trial end date:
2023-11-10
Target enrollment:
Participant gender:
Summary
Monocentric randomized phase I/II trial, including 24 patients diagnosed with relapsing
glioblastoma (GBM) irrespective of MGMT and IDH gene status.
Following diagnosis of relapsing glioblastoma by either brain CT scan or MRI, patients will
be randomized in 2 arms:
1. Arm 1: IMA950 mixed with Poly-ICLC administered subcutaneously
2. Arm 2: Pembrolizumab 200mg q3w IV and IMA950 mixed with Poly-ICLC administered
subcutaneously
The first phase of treatment will last 6 weeks, then surgery will be performed (done if
clinically possible ad indicated). In case of available brain tissue, extensive analysis of
the tumor immune response will be performed. Assessment of systemic immune response by PBMC
immunomonitoring will be systematically done before and after surgery.